157
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Female is Associated with Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes

ORCID Icon, , , , &
Pages 2355-2364 | Received 17 May 2023, Accepted 27 Jul 2023, Published online: 07 Aug 2023

References

  • Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693–1702. doi:10.1161/CIRCULATIONAHA.119.042375
  • Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:Cd013650. doi:10.1002/14651858.CD013650.pub2
  • Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583–1587. doi:10.1126/science.1112062
  • Catalan M, Herreras Z, Pinyol M, et al. Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. Nutr Metab Cardiovasc Dis. 2015;25(8):742–748. doi:10.1016/j.numecd.2015.04.009
  • Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. doi:10.1016/0002-9149(74)90089-7
  • Laverty AA, Bottle A, Kim SH, et al. Gender differences in hospital admissions for major cardiovascular events and procedures in people with and without diabetes in England: a nationwide study 2004–2014. Cardiovasc Diabetol. 2017;16:100. doi:10.1186/s12933-017-0580-0
  • Malmborg M, Schmiegelow MDS, Nørgaard CH, et al. Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men? Eur Heart J. 2020;41:1346–1353. doi:10.1093/eurheartj/ehz913
  • Murtaza G, Virk HUH, Khalid M, et al. Diabetic cardiomyopathy - a comprehensive updated review. Prog Cardiovasc Dis. 2019;62:315–326. doi:10.1016/j.pcad.2019.03.003
  • Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European Association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29:277–314. doi:10.1016/j.echo.2016.01.011
  • Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121–141. doi:10.1161/CIRCRESAHA.118.311371
  • Roberts AW, Clark AL, Witte KK. Review article: left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease — do we need to screen our patients? Diab Vasc Dis Res. 2009;6(3):153–163. doi:10.1177/1479164109338774
  • Dillmann WH. Diabetic cardiomyopathy. Circ Res. 2019;124(8):1160–1162. doi:10.1161/CIRCRESAHA.118.314665
  • Jensen MT, Fung K, Aung N, et al. Changes in cardiac morphology and function in individuals with diabetes mellitus: the UK biobank cardiovascular magnetic resonance substudy. Circ Cardiovasc Imaging. 2019;12(9):e009476. doi:10.1161/CIRCIMAGING.119.009476
  • Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41(36):3421–3432. doi:10.1093/eurheartj/ehaa419
  • Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5
  • Šuran D, Kanič V, Naji F, et al. Predictors of early cardiac changes in patients with type 1 diabetes mellitus: an echocardiography-based study. Bosn J Basic Med Sci. 2019;19:384–391. doi:10.17305/bjbms.2019.4250
  • Jensen MT, Sogaard P, Andersen HU, et al. Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand and 1 Study. Diabetologia. 2014;57:672–680. doi:10.1007/s00125-014-3164-5
  • Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144–153. doi:10.1038/nrendo.2015.216
  • Sonaglioni A, Barlocci E, Adda G, et al. The impact of short-term hyperglycemia and obesity on biventricular and biatrial. Nutrition, Metabolism and Cardiovascular Diseases. 2022;32(2):456–468.
  • Toedebusch R, Belenchia A, Pulakat L. Diabetic cardiomyopathy: impact of biological sex on disease development and molecular signatures. Front Physiol. 2018;9:453. doi:10.3389/fphys.2018.00453
  • Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34:309–338. doi:10.1210/er.2012-1055
  • Karas RH, Schulten H, Pare G, et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res. 2001;89:534–539. doi:10.1161/hh1801.097239
  • Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135:54–70. doi:10.1016/j.pharmthera.2012.03.007
  • Wu Y, Shen Y, Kang K, et al. Effects of estrogen on growth and smooth muscle differentiation of vascular wall-resident CD34(+) stem/progenitor cells. Atherosclerosis. 2015;240:453–461. doi:10.1016/j.atherosclerosis.2015.04.008
  • Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8:33. doi:10.1186/s13293-017-0152-8
  • Chodari L, Mohammadi M, Ghorbanzadeh V, Dariushnejad H, Mohaddes G. Testosterone and voluntary exercise promote angiogenesis in hearts of rats with diabetes by enhancing expression of VEGF-A and SDF-1a. Can J Diabetes. 2016;40:436–441. doi:10.1016/j.jcjd.2016.03.004
  • Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. doi:10.1136/bmj.m997
  • Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37:278–316. doi:10.1210/er.2015-1137